Verici Dx Plc VRCI
LSE · United Kingdom · Health Services
GBp 0.2250+0.02 (+7.14%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
FRANKLIN, Tenn., June 24, 2026--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). The Company also received NY state approval of Tutivia™, its blood-based laboratory developed test (LDT) that delivers predictive, data-driven intelligence in the form of an easy-to-interpret risk score clas
FRANKLIN, Tenn., June 17, 2026--Verici Dx, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced that collaborators will present new data on the predictive performance of its Tutivia™ test at the American Transplant Congress (ATC) Annual Meeting, taking place June 20–24, 2026 in Boston. The abstracts are available via the planner on the ATC website.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.